Swiss Cancer Institute clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20
What changed in the last 30 days
5 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 2 with minor changes only.
- Notable: salVage · Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified
- Stopped: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Trial terminated
- Minor: Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) Primary completion pushed from Jul 16, 2026 to Dec 7, 2026
- Minor: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy · MIBC Primary completion date changed from estimate of Jun 2026 to Apr 26, 2026
- Notable: CtDNA and PET-oriented Therapy · DLBCL A Multicenter, Open-label, Phase II Trial Primary completion pushed from Jul 30, 2026 to Jan 30, 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 2 | 15 | |
| Phase 2/3 | 1 |
Not charted: 4 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 12
Lung Cancer (7) · Non-Small Cell Lung Cancer (NSCLC) (6) · Non-Hodgkin Lymphoma (3) · Prostate Cancer (3) · Breast Cancer (2) · Bladder Cancer (1) · Colorectal Cancer (1) · DLBCL (1) · Melanoma (1) · Sarcoma (1)
Get alerts when Swiss Cancer Institute's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.